Tempest Therapeutics adjourned its reconvened special meeting on August 17, 2026, because the proposal to replace supermajority voting requirements and permit stockholder action by written consent failed to receive the required 75% affirmative vote. The company will reconvene the meeting on September 15, 2026, to seek approval for the same amendment. Tempest Therapeutics operates in the biotechnology industry.
